A novel chemical process has been devised for the synthesis of a new derivative of
gossypol, 6,7,6',7'-tetrahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2']binaphthalenyl-1,4,1',4'-tetraone (
Apogossypolone). This new process has only four steps, with a shorter synthesis span, a simple purification process, and improved yield and quality. The structure of
apogossypolone was characterized by( 1)H-nuclear magnetic resonance, (13)C-nuclear magnetic resonance, mass spectroscopy, infrared spectroscopy, and elemental analysis. Cell-cytotoxicity assay demonstrates that
apogossypolone is three- to six-fold more potent than the parent compound, (-)-
gossypol, in inhibiting the human prostate tumor cell lines PC-3 and DU-145 as well as the human
breast cancer cell line MDA-MB-231. The colony-formation assay with DU-145 cells showed that
apogossypolone inhibited more than 70% of colony formation at 1 muM, whereas (-)-
gossypol at 10 muM only inhibited less than 50% of colony formation. The results indicate that
apogossypolone exerts strong antitumor activities in human prostate and
breast cancer cells, and thus represents a promising
cancer therapeutic.